Recipharm

Recipharm's mission is to be the leading global CDMO, providing the full spectrum of pharmaceutical development and manufacturing services to enable its clients to bring vital medicines to patients faster and more efficiently. The company has achieved a top-five global position through a disciplined acquisition strategy, building a diversified technological portfolio and a resilient international network. Its core strategy focuses on deepening capabilities in high-growth areas like biologics and sterile injectables, while leveraging its scale and integration to drive operational excellence and sustainable growth.

A comprehensive, non-proprietary service platform encompassing pharmaceutical development, drug product manufacturing (oral solids, semi-solids, liquids, HPAPIs), sterile fill-finish, biologics manufacturing, and packaging services for all major therapeutic areas.

Recipharm competes in the top tier of global CDMOs against firms like Lonza, Catalent, and Thermo Fisher Scientific. Its primary advantages are its diversified technology portfolio, owned global network, and integration expertise, though it faces competition from both large integrated players and nimble specialists in high-growth niches.